Form 4: Enliven Therapeutics Director Richard A. Heyman Reports Stock Sale

Director Richard A. Heyman of Enliven Therapeutics, Inc. reports the sale of 1,270 shares of common stock at an average price of $24.8006.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc., filed a Form 4 disclosing a transaction involving the company's common stock.
• On July 15, 2024, Heyman sold 1,270 shares of common stock at a weighted average price of $24.8006.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on July 17, 2023.
• Following the transaction, Heyman directly owns 133,345 shares of common stock.
• Heyman also indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 28,567 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock sales under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. The sale was conducted under a pre-arranged trading plan, which is a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale by a director could have a minor negative impact on shareholder sentiment, but the pre-arranged trading plan mitigates this concern.

Key Dates